AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
Zacks Investment Research on MSN
Buy AbbVie stock before Q4 earnings? Here's what to know
AbbVie ABBV is set to report fourth-quarter and full-year 2025 earnings on Feb. 4, before the opening bell. The Zacks ...
1don MSN
Where will AbbVie be in 5 years?
A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.
One of the better-quality companies in the pharmaceutical sector, AbbVie ( ABBV 2.35%) had a phenomenal year in 2025.
Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.
AbbVie secures revenues after patent expiration for Humira through growth of immunology and neurology franchises. Credit: ChrisStock82/Shutterstock.com Humira ...
Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...
AbbVie Inc.’s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company’s current president and chief operating officer, Robert Michael.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results